Integrating Oral SERDs: HR+/HER2- BC
Integrating Oral SERDs Into Treatment for Patients With HR-positive/HER2-negative Metastatic Breast Cancer and Current Rationale or Medical Need

Released: November 13, 2024

Expiration: November 12, 2025

Virginia Kaklamani
Virginia Kaklamani, MD, DSc
Erica L. Mayer
Erica L. Mayer, MD, MPH
Laura M. Spring
Laura M. Spring, MD

Activity

Progress
1
Course Completed